Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Elosulfase Alfa

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    NICE does not recommend elosulfase alfa for Morquio A syndrome
    NICE does not recommend elosulfase alfa for Morquio A syndrome

    16 Nov 2021

    // Anna Begley EUROPEANPHARMACEUTICALREVIEW

    https://www.europeanpharmaceuticalreview.com/news/165514/nice-does-not-recommend-elosulfase-alfa-for-morquio-a-syndrome/

    Anna Begley EUROPEANPHARMACEUTICALREVIEW
    16 Nov 2021
    Share Share
    BioMarin's Vimizim (elosulfase alfa) Receives Supplemental Approval in US
    BioMarin's Vimizim (elosulfase alfa) Receives Supplemental Approval in US

    04 Dec 2019

    // FDA

    https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125460

    FDA
    04 Dec 2019
    Share Share
    BioMarin Announces Approval of Vimizim
    BioMarin Announces Approval of Vimizim

    04 Jun 2019

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/biomarin-announces-approval-of-vimizim-elosulfase-alfa-in-china-for-treatment-of-morquio-a-syndrome-300861353.html

    PR NEWSWIRE
    04 Jun 2019
    Share Share
    BioMarin investing $43M in fill-finish line at plant in Ireland
    BioMarin investing $43M in fill-finish line at plant in Ireland

    04 Sep 2018

    // Eric Palmer FIERCE PHARMA

    https://www.fiercepharma.com/manufacturing/biomarin-investing-43m-fill-finish-line-at-plant-ireland

    Eric Palmer FIERCE PHARMA
    04 Sep 2018
    Share Share